incretin and glp-1 The time has come for incretins, a long time coming | Journal of Molecular Medicine Incretin-based therapy of metabolic disease

Bariatric surgery patients experience it at even higher rates (5070%)

Eli Lillys orforglipron, an oral GLP-1 receptor agonist, has demonstrated comparable efficacy to injectable versions, offering a more convenient option for patients

JSTOR 4089339

Ging nh tt c cc ngun cht x, n c th gy au d dy, y hi v y hi nu dng liu ln hn bnh thng

Moreover, as a small molecule drug, it could increase the confidence of in-depth research to find oral GLP-1RAs in the treatment of chronic pain

Pre-clinical studies demonstrate cardioprotective effects of GLP-1 agonists and favor the view that inhibition of DPP-4 resulting in increased levels of GLP-1 is one of the major pathways for CV protection by DPP-4 inhibitors [11, 12]